Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05378464). This is a study registration, not published results. Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute. Recruitment status: SUSPENDED. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 28 participants (ESTIMATED). Conditions: HER2-positive Breast Cancer. Interventions: BIOLOGICAL: Dendritic Cell (DC1) Vaccine; DRUG: Trastuzumab; DRUG: Pepinemab; BIOLOGICAL: T-Cell therapy. Primary outcome measures: Maximum Tolerated Dose (MTD) of expanded CD4 T cells , Up to 6 months. Brief summary: The purpose of this study is to test the safety of Adoptive T-Cell therapy following the Dendritic Cell (DC1) study vaccine given in combination with pepinemab added to standard of care therapy, trastuzumab to help people with HER2 positive breast cancer.